{
    "nct_id": "NCT05337137",
    "official_title": "A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma",
    "inclusion_criteria": "* Histologically confirmed advanced/metastatic hepatocellular carcinoma (HCC)\n* Naïve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with BMS medical team)\n* Child-Pugh score of 5 or 6 (ie, Child-Pugh A)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC\n* Prior allogenic stem cell or solid organ transplantation\n* Untreated symptomatic central nervous system (CNS) metastases\n* Clinically significant ascites as defined by:\n\n  i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}